Vaccine panel says Canada can delay second dose of COVID-19 vaccine

Modesto Morganelli
Gennaio 14, 2021

If President-elect Joe Biden's administration is able to sufficiently ramp up vaccination rates to meet anticipated levels of production, herd immunity could be reached this August, Airfinity estimated. That, in turn, triggers an immune response.

Speaking Wednesday at a JPMorgan Healthcare Conference event, Slaoui said he expects the J&J shot to have 80 per cent to 85 per cent efficacy, surpassing the objective the company outlined in its clinical trial design. Said Carlos del Rio, a distinguished professor at the Emory University School of Medicine: "The proof is in the pudding".

The centre, believed to be the first to open inside a supermarket in England, will operate at an Asda branch in Birmingham from the week starting on January 25.

"That point came so close to the final analysis that we decided not to do an interim analysis", Stoffels said.

There are two Phase 3 studies running. To start, it's only confirmed component is to provide users with credible, factual information about COVID-19 vaccine safety through Uber's consumer app, but the companies have also discussed additional "options" including building ride scheduling via Uber directly into the immunization appointment booking process.

Del Rio is optimistic.

Critically, unlike the Covid-19 shots developed by Pfizer and BioNTech or Moderna, only one dose of its shot was needed and the vaccine could be stored in normal refrigerators.

"We're on track to have every Canadian who wants a vaccine, to receive one by September", he said.

Pfizer and BioNTech have recommended their vaccine be administered in two doses, 21 days apart.

But as the pandemic heats up and vaccine supplies are slow to trickle in, they say delaying the second dose up to six weeks, instead of three or four, could more quickly get at least some protection against COVID-19 to more people.

By June, it is expected that more than half of the country will have the ability to be vaccinated. "It's nearly equally hard to scale up manufacturing at that level so fast as it was to develop the vaccine".

Carlo de Natoristefani, lead manufacturing adviser for the "Operation Warp Speed" programme, as Washington's vaccine development programme is known, said that J&J might be able catch up by March.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE